Metformin use is associated with better survival of breast cancer patients with diabetes: A meta-analysis

Oncologist

Volumn 20, Issue 11, 2015, Pages 1236-1244

  Xu, Hong ^a   Chen, Kai ^a   Jia, Xiaoyan ^b   Tian, Yali ^d   Dai, Yun ^a   Li, Dapeng ^a   Xie, Jing ^a   Tao, Min ^a,c   Mao, Yixiang ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Institute of Clinical Immunology of Jiangsu Province   (China)

^d Department of Oncology Suzhou Xiangcheng People's Hospital   (China)

Author keywords

Breast cancer; Diabetes mellitus; Meta analysis; Metformin; Survival

Indexed keywords

HORMONE RECEPTOR; METFORMIN;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DIABETES MELLITUS; HUMAN; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; METFORMIN; NEOADJUVANT THERAPY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84946542679     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0096     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Alimova IN, Liu B, Fan Z et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8: 909-915.
3. Goodwin PJ. Insulin in the adjuvant breast cancer setting: A novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 2008;26:833-834.
4. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008;67:1-7.
5. Jiralerspong S, Palla SL, Giordano SH et al. Met for min and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-3302.
6. Lee JH, Kim TI, Jeon SM et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012; 131:752-759.
7. Yin M, Zhou J, Gorak EJ et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. The Oncologist 2013;18: 1248-1255.
8. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
9. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines forreportingobservationalstudies. Lancet 2007; 370: 1453-1457.
10. Barone BB, Yeh HC, Snyder CF et al. Long-term all-cause mortalityin cancer patients with preexist-ingdiabetesmellitus: Asystematicreviewand meta-analysis. JAMA 2008;300:2754-2764.
11. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
13. Egger M, Davey Smith G, Schneider M et al. Biasin meta-analysis detected bya simple,graphical test. BMJ 1997;315:629-634.
14. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463.
15. Sun B, Hou G, Zhang X et al. Clinicopathologic characteristics and prognostic analysis of luminal B breast cancer patients with diabetes. Chinese J Clin Oncol 2013;40:1042-1046.
16. Hou G, Zhang S, Zhang X et al. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013;137:807-816.
17. Aksoy S, Sendur MAN, Altundag K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Med Oncol 2013;30:590.
18. Kim H, Ahn SH. Impact of metformin in luminal subtype breast cancer. Eur J Cancer 2013;49:S467.
19. Currie CJ, Poole CD, Jenkins-Jones S et al. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012;35:299-304.
20. Luo J, Virnig B, Hendryx M et al. Diabetes, diabetes treatment and breast cancer prognosis. Breast Cancer Res Treat 2014;148:153-162.
21. Bayraktar S, Hernadez-Aya LF, Lei X et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012;118:1202-1211.
22. He X, Esteva FJ, Ensor J et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012;23: 1771-1780.
23. Lega IC, Austin PC, Gruneir A et al. Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 2013;36:3018-3026.
24. Peeters PJHL, Bazelier MT, Vestergaard P et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013;8:357-363.
25. Zhu W. Effect of mefformin on prognosis of breast cancer patients complicated with type 2 diabetes mellitus [Master’s Thesis]. Jinan, China: Shandong University; 2013.
26. Zhao J. Effect of metformin on survival outcomes in estrogen receptor positive breast cancer patients with diabetes [Master’s Thesis]. Hangzhou, China: Zhejiang University; 2012.
27. Cleveland RJ, North KE, Stevens J et al. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. CancerCauses Control 2012;23:1193-1203.
28. El-Benhawy SA, El-Sheredy HG. Metformin and survival in diabetic patients with breast cancer. J Egypt Public Health Assoc 2014;89:148-153.
29. Xu H, Aldrich MC, Chen Q et al. Validating drug repurposing signals using electronic health records: A case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 2015;22: 179-191.
30. Oppong BA, Pharmer LA, Oskar S et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 2014;3: 1025-1034.
31. Xiao Y, Zhang S, Hou G et al. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol 2014;35:2035-2045.
32. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2014;16:707-710.
33. Johnson JA, Gale EA. Diabetes, insulin use, and cancer risk: Are observational studies part of the solution-or part of the problem? Diabetes 2010;59: 1129-1131.
34. Bowker SL, Yasui Y, Veugelers P et al. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 2010;53:1631-1637.
35. Sadeghi N, Abbruzzese JL, Yeung SCJ et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-2912.
36. Terrin N, Schmid CH, Lau J et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113-2126.
37. Peters JL, Sutton AJ, Jones DR et al. Performance of the trim and fill method in the presence of publication bias and between-studyheterogeneity. Stat Med 2007;26:4544-4562.
38. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16:1695-1700.
39. Jiralerspong S, Kim ES, Dong W et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 2013; 24:2506-2514.
40. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005;2:48-53.
41. Ming Yin, Jie Zhou, Edward J. Goraketal. Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis. The Oncologist 2013;18:1248-1255.